U.S. Stem Cell, Inc.
http://us-stemcell.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From U.S. Stem Cell, Inc.
MTI 100: Macro Challenges Make Demands Of Newly Resilient Medtechs
Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.
Teleflex Expands Interventional Urology Business By Acquiring Palette For 12X Sales
Teleflex markets the UroLift minimally invasive system for managing symptomatic benign prostate hyperplasia. Palette sells five urology products, including Barrigel spacer gel for prostate radiotherapy.
Single Port, Single Vision: Titan’s New Exec Speaks On Reshaping Robotics Strategy
Operating on slim margins towards the launch of its Enos single port surgical robot, Titan Medical needs to refocus its efforts to succeed, according to its new CEO Cary Vance.
Exec Chat: 'Wow Factor' Is Important in Medtech Investment, But It’s Not Everything Says Ceros CEO
Medtech Insight interviewed the CEO of Ceros Financial Services and its investment banking division, Ceros Capital Markets, about the firm’s considerations for funding early-stage medtechs, and outlook for medtech fundraising, in this uncertain economic climate.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Bioheart Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice